Iothalamate meglumine
Angio-conray, Conray, Cysto-conray, Vascoray (iothalamate meglumine) is a small molecule pharmaceutical. Iothalamate meglumine was first approved as Conray on 1982-01-01.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
Conray, Cysto-conray (discontinued: Conray)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Iothalamate meglumine
+
Iothalamate sodium
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| VASCORAY | Mallinckrodt | N-016783 DISCN | 1982-01-01 | 1 products |
Hide discontinued
Iothalamate meglumine
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| CONRAY | Liebel-Flarsheim | N-013295 RX | 1982-01-01 | 1 products, RLD, RS |
| CYSTO-CONRAY II | Liebel-Flarsheim | N-017057 RX | 1982-01-01 | 1 products |
Show 2 discontinued
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| conray | New Drug Application | 2023-05-11 |
| cysto-conray | New Drug Application | 2010-07-08 |
| cysto-conray ii | New Drug Application | 2020-12-31 |
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
No data
HCPCS
No data
Clinical
Clinical Trials
11 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hypertension | D006973 | EFO_0000537 | I10 | — | 1 | 1 | — | — | 1 |
Indications Phases 2
No data
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Congenital abnormalities | D000013 | EFO_0003915 | Q89.9 | 1 | — | — | — | — | 1 |
| Urologic diseases | D014570 | — | N39.9 | 1 | — | — | — | — | 1 |
| Neoplasms | D009369 | — | C80 | 1 | — | — | — | — | 1 |
| Non-small-cell lung carcinoma | D002289 | — | — | 1 | — | — | — | — | 1 |
| Lung neoplasms | D008175 | — | C34.90 | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Kidney diseases | D007674 | EFO_0003086 | N08 | — | — | — | — | 5 | 5 |
| Renal insufficiency | D051437 | — | N19 | — | — | — | — | 2 | 2 |
| Kidney transplantation | D016030 | — | — | — | — | — | — | 1 | 1 |
| Sickle cell anemia | D000755 | EFO_0000697 | D57 | — | — | — | — | 1 | 1 |
| Liver failure | D017093 | — | K72.9 | — | — | — | — | 1 | 1 |
| Ischemia | D007511 | EFO_0000556 | — | — | — | — | — | 1 | 1 |
| Myocardial ischemia | D017202 | EFO_1001375 | I20-I25 | — | — | — | — | 1 | 1 |
| Chronic renal insufficiency | D051436 | — | N18 | — | — | — | — | 1 | 1 |
| Diagnosis | D003933 | — | — | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Iothalamate meglumine |
| INN | — |
| Description | Iotalamic acid is an organic molecular entity. |
| Classification | Small molecule |
| Drug class | iodine-containing contrast media |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | CNC(=O)c1c(I)c(NC(C)=O)c(I)c(C(=O)O)c1I.CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO |
Identifiers
| PDB | — |
| CAS-ID | 2276-90-6 |
| RxCUI | 1546451 |
| ChEMBL ID | CHEMBL1201125 |
| ChEBI ID | — |
| PubChem CID | 3737 |
| DrugBank | DB09133 |
| UNII ID | — |
Target
No data
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 2,180 documents
View more details
Safety
Black-box Warning
Black-box warning for: Conray, Cysto-conray, Cysto-conray ii
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
328 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use